A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR- tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal.

Slides:

Advertisements

Similar presentations

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Cai-Hong.

Advertisements

A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation Fumio Imamura, Takako Inoue, Madoka Kimura,

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA Tomomi Nakamura, MD, Naoko.

Chee-Seng Tan, MRCP, David Gilligan, FRCPE, Dr Simon Pacey, FRCP

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Hiromasa Nakayasu, Toshihiro Shirai, Yuko Tanaka, Mika Saigusa

Volume 355, Issue 2, Pages (December 2014)

Lung cancer in patients diagnosed with silicosis should be investigated Adil Can Güngen, Yusuf Aydemir, Hikmet Çoban, Hasan Düzenli, Canantan Tasdemir

Volume 22, Issue 6, Pages (December 2012)

Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients Gene Y. Cho, Lucas.

Zhao Jing, M. D. , Zhang Qiong, M. D. , Wang Yonggang, M. D

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT Zhen-Yu He, San-Gang Wu, Fang Peng,

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Anastasia A. Theodosiou, Martin H. Johnson

c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Ret mouse very large tumors (VLTs) display altered ratios of infiltrating memory to naive T cells: Roles in tumor expansion Mohammad W. Khan, Viktor.

Cell signaling and cancer

Hypothermic protection in traumatic brain injury

Deregulating EMT and Senescence: Double Impact by a Single Twist

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR Marie.

Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation Diogo D.G. Bugano, Neda Kalhor,

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Geoffrey R. Oxnard, MD, Vincent A. Miller, MD, Mark E

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report Lore Helene Braun, Stefan.

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First- line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

Volume 19, Issue 4, Pages (April 2017)

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

Volume 10, Issue 5, Pages (November 2005)

The development of a forensic clock to determine time of death

Maxime Janin, Manel Esteller Cell Metabolism

Characterizing the Killer Colorectal Carcinomas

Deregulating EMT and Senescence: Double Impact by a Single Twist

Volume 22, Issue 6, Pages (December 2012)

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib Helena A. Yu,

Matthew D. Hellmann, MD, Boris Reva, PhD, Helena Yu, MD, Valerie W

Volume 152, Issue 1, (January 2013)

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Volume 54, Issue 5, Pages (May 2011)

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer Katrina Woodford, Vanessa Panettieri, Trieumy Tran Le,

The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer Yukito Ichinose, MDa, Tokujiro.

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Automated addition of Chelex solution to tubes containing trace items

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component Yang Zhang, MD, Rui Wang, PhD,

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains Chenguang Li, MD,

Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA Tomomi Nakamura, MD, Naoko.

Ret mouse very large tumors (VLTs) display altered ratios of infiltrating memory to naive T cells: Roles in tumor expansion Mohammad W. Khan, Viktor.

The posterior cerebellum, a new organ at risk?

An interstitial hypothesis for breast cancer related lymphoedema

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib Kenichi.

Colombian results of the interlaboratory quality control exercise 2015

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Spatial change in the risks of Plasmodium vivax and Plasmodium falciparum malaria in China, 2005–2014 Samuel Hundessa, Gail Williams, Wenyi Zhang, Shanshan.

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

Volume 148, Issue 1, (January 2012)

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Presentation transcript:

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR- tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition Nana Zhang, Depu Wang, Xiaofeng Li, Zhe Yang, Guanjun Zhang, Yili Wang, Chunbao Wang Respiratory Medicine Case Reports Volume 22, Pages 183-186 (January 2017) DOI: 10.1016/j.rmcr.2017.08.015 Copyright © 2017 Terms and Conditions

Fig. 1 The H&E staining tumor tissue and immunohistochemistry staining tumor tissues for TTF-1, E-cadherin and Vimentin phenotypes. The primary tumor tissues(A,C,E,G). The primary tumor showed moderate differentiated adenocarcinoma(A). The TTF-1 and E-cadherin were positive in the differentiated cancerous tissue but attenuated in the tumor cell clusters(which is indicated by the red arrow in the figure) in the invasive margin of the cancer(C,E). Vemintin were positive in the tumor cell clusters(indicated by the arrow) in the invasive margin of the cancer (G). The expectoration of recurred tumor tissue block(B,D,F,H). The recurred tumor tissue showed, TTF-1,E-cadherin and Vimentin stained sections. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Respiratory Medicine Case Reports 2017 22, 183-186DOI: (10.1016/j.rmcr.2017.08.015) Copyright © 2017 Terms and Conditions